EURX Eurand N.V. (MM)

Eurand Invites Public to Listen to Webcast MILAN, Italy, Aug. 24 /PRNewswire-FirstCall/ -- Eurand N.V. (NASDAQ:EURX), a specialty pharmaceutical company that develops enhanced pharmaceutical and biopharmaceutical products based on its proprietary drug formulation technologies, is scheduled to present at the Thomas Weisel Partners Healthcare Conference in Boston, Massachusetts on Wednesday, September 5, 2007. Gearoid Faherty, Eurand's Chief Executive Officer, is scheduled to speak to conference attendees at 10:55 am Eastern Daylight Time (4:55 pm Central European Summer Time). A live audio webcast of this event will be available to the general public by visiting Eurand's website at http://www.eurand.com/. Following the live webcast, an archived version of the call will be available at the same website. About Eurand Eurand is a specialty pharmaceutical company that develops enhanced pharmaceutical and biopharmaceutical products based on its proprietary drug formulation technologies. Eurand has had four products approved by the FDA since 2000 and has a pipeline of product candidates in development for itself and its collaboration partners. Eurand has completed two phase III clinical trials on its lead product candidate, Zentase(TM), for the treatment of Exocrine Pancreatic Insufficiency and filed the first segment of its rolling NDA for this product in June 2007. Eurand's technology platforms include bioavailability enhancement of poorly soluble drugs, customized release, taste-making/fast-dissolving formulations and drug conjugation. Eurand is a global company with facilities in the USA and Europe. For more information, visit Eurand's website at http://www.eurand.com/. This release, and oral statements made with respect to information contained in this release, constitutes forward-looking statements. Such forward-looking statements include those which express plan, anticipation, intent, contingency, goals, targets or future development and/or otherwise are not statements of historical fact including, but not limited to our plans for our NDA filing, enrollment and future plans for our clinical trials, progress of and reports of results from clinical studies, clinical development plans and product development activities. The words "potentially", "could", "calls for" and similar expressions also identify forward-looking statements. These statements are based upon management's current expectations and are subject to risks and uncertainties, known and unknown, which could cause actual results and developments to differ materially from those expressed or implied in such statements. Factors that could affect actual results include risks associated with the possibility that the FDA refuses to approve our NDA; the outcome of any discussions with the FDA; and unexpected delays in preparation of materials for submission to the FDA as a part of our NDA filing. Forward- looking statements contained in this press release are made as of this date, and we undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Actual events could differ materially from those anticipated in the forward- looking statements. CONTACTS: Marian Cutler Nick Laudico/Elizabeth Scott Vice President, The Ruth Group Corporate Communications +1.646-536-7030 / 7014 Eurand +1.267.759.9324 DATASOURCE: Eurand CONTACT: Marian Cutler, Vice President, Corporate Communications, Eurand, +1-267-759-9324, ; Nick Laudico, +1-646-536-7030, or Elizabeth Scott, +1-646-536-7014, , of The Ruth Group Web site: http://www.eurand.com/

Copyright